Table 2 The list of 100 most cited cannabis and cannabinoid-related manuscripts

1

Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., ... & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258 (5090), 1946–1949.

2

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346 (6284), 561–564.

3

Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365 (6441), 61–65.

4

Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., ... & Pertwee, R. G. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50 (1), 83–90.

5

Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., ... & Mechoulam, R. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews, 54 (2), 161–202.

6

Devane, W. A., Dysarz, F. 3., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34 (5), 605–613.

7

Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H. H., Sørgård, M., Di Marzo, V., ... & Högestätt, E. D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400 (6743), 452–457.

8

Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., De Costa, B. R., & Rice, K. C. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences, 87 (5), 1932–1936.

9

Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., ... & Ferrara, P. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters, 350 (2–3), 240–244.

10

Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience, 11 (2), 563–583.

11

Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384 (6604), 83–87.

12

Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., ... & Waku, K. (1995). 2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications, 215 (1), 89–97.

13

Mountjoy, K. G., Robbins, L. S., Mortrud, M. T., & Cone, R. D. (1992). The cloning of a family of genes that encode the melanocortin receptors. Science, 257 (5074), 1248–1251.

14

Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience, 4 (11), 873–884.

15

Jordt, S. E., Bautista, D. M., Chuang, H. H., McKemy, D. D., Zygmunt, P. M., Högestätt, E. D., ... & Julius, D. (2004). Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature, 427 (6971), 260–265.

16

Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C., & Piomelli, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372 (6507), 686–691.

17

Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet, 370 (9584), 319–328.

18

Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., ... & Di Marzo, V. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature, 418 (6897), 530–534.

19

Tsou, K., Brown, S., Sanudo-Pena, M. C., Mackie, K., & Walker, J. M. (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 83 (2), 393–411.

20

Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58 (3), 389–462.

21

Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., ... & Kunos, G. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410 (6830), 822–825.

22

Pertwee, R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics, 74 (2), 129–180.

23

Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., Rössner, S., & RIO-Europe Study Group. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. The Lancet, 365 (9468), 1389–1397.

24

Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., ... & Giustino, A. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine, 9 (1), 76–81.

25

Stella, N., Schweitzer, P., & Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388 (6644), 773–778.

26

Wilson, R. I., & Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 410 (6828), 588–592.

27

Després, J. P., Golay, A., & Sjöström, L. (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine, 353 (20), 2121–2134.

28

Freund, T. F., Katona, I., & Piomelli, D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiological Reviews, 83 (3), 1017–1066.

29

Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., ... & Casellas, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry, 232 (1), 54–61.

30

Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J. F., Beslot, F., ... & Vassart, G. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 283 (5400), 401–404.

31

Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Sciences, 98 (16), 9371–9376.

32

Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., ... & De Vos, W. M. (2013). Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences, 110 (22), 9066–9071.

33

Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., ... & Marnett, L. J. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 310 (5746), 329–332.

34

Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group. (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 295 (7), 761–775.

35

Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., ... & Piomelli, D. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences, 99 (16), 10,819–10,824.

36

Wilson, R. I., & Nicoll, R. A. (2002). Endocannabinoid signaling in the brain. Science, 296 (5568), 678–682.

37

Cota, D., Marsicano, G., Tschöp, M., Grübler, Y., Flachskamm, C., Schubert, M., ... & Tomassoni, F. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. The Journal of Clinical Investigation, 112 (3), 423–431.

38

Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., ... & Poulton, R. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry, 57 (10), 1117–1127.

39

Calignano, A., La Rana, G., Giuffrida, A., & Piomelli, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394 (6690), 277–281.

40

Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. Journal of Neuroscience, 19 (11), 4544–4558.

41

Tanda, G., Pontieri, F. E., & Di Chiara, G. (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science, 276 (5321), 2048–2050.

42

Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., ... & López-Rodríguez, M. L. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science, 302 (5642), 84–88.

43

Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Sciences, 96 (10), 5780–5785.

44

Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., ... & Kunos, G. (2005). Endocannabinoid activation at hepatic CB 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. The Journal of Clinical Investigation, 115 (5), 1298–1305.

45

Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., ... & Mechoulam, R. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacological Reviews, 62 (4), 588–631.

46

Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009). Endocannabinoid-mediated control of synaptic transmission. Physiological Reviews, 89 (1), 309–380.

47

Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ, 325 (7374), 1212–1213.

48

Suzuki, A., Josselyn, S. A., Frankland, P. W., Masushige, S., Silva, A. J., & Kida, S. (2004). Memory reconsolidation and extinction have distinct temporal and biochemical signatures. Journal of Neuroscience, 24 (20), 4787–4795.

49

Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N. O., Leonova, J., ... & Greasley, P. J. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152 (7), 1092–1101.

50

Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., ... & Kamerman, P. R. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet Neurology, 14 (2), 162–173.

51

Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987). Cannabis and schizophrenia A longitudinal study of Swedish conscripts. The Lancet, 330 (8574), 1483–1486.

52

Wise, R. A. (1996). Neurobiology of addiction. Current Opinion in Neurobiology, 6 (2), 243–251.

53

van Os, J., Kenis, G., & Rutten, B. P. (2010). The environment and schizophrenia. Nature, 468 (7321), 203–212.

54

Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., ... & Gangadharan, U. (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. Journal of Cell Biology, 163 (3), 463–468.

55

Tchernof, A., & Després, J. P. (2013). Pathophysiology of human visceral obesity: an update. Physiological Reviews, 93 (1), 359–404.

56

Watanabe, H., Vriens, J., Prenen, J., Droogmans, G., Voets, T., & Nilius, B. (2003). Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature, 424 (6947), 434–438.

57

Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277 (5329), 1094–1097.

58

Millan, M. J. (2003). The neurobiology and control of anxious states. Progress in Neurobiology, 70 (2), 83–244.

59

Di Marzo, V., Bifulco, M., & De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery, 3 (9), 771–784.

60

Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370 (23), 2219–2227.

61

Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. The Lancet, 370 (9600), 1706–1713.

62

Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., ... & Mitchell, R. L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Molecular Pharmacology, 48 (3), 443–450.

63

Wise, R. A. (1996). Addictive drugs and brain stimulation reward. Annual Review of Neuroscience, 19 (1), 319–340.

64

Deutsch, D. G., & Chin, S. A. (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochemical Pharmacology, 46 (5), 791–796.

65

Kreitzer, A. C., & Regehr, W. G. (2001). Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron, 29 (3), 717–727.

66

Ohno-Shosaku, T., Maejima, T., & Kano, M. (2001). Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron, 29 (3), 729–738.

67

Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chemistry & Biology, 14 (12), 1347–1356.

68

Giuffrida, A., Parsons, L. H., Kerr, T. M., De Fonseca, F. R., Navarro, M., & Piomelli, D. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience, 2 (4), 358–363.

69

Mackie, K., & Hille, B. (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences, 89 (9), 3825–3829.

70

Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., ... & Davis, J. B. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). British Journal of Pharmacology, 129 (2), 227–230.

71

Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2004). Causal association between cannabis and psychosis: examination of the evidence. The British Journal of Psychiatry, 184 (2), 110–117.

72

Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J. M., Casellas, P., Congy, C., ... & Portier, M. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics, 284 (2), 644–650.

73

Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., ... & Lichtman, A. H. (2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nature Chemical Biology, 5 (1), 37–44.

74

Dewey, W. L. (1986). Cannabinoid pharmacology. Pharmacological Reviews, 38 (2), 151–178.

75

Ameri, A. (1999). The effects of cannabinoids on the brain. Progress in Neurobiology, 58 (4), 315–348.

76

Hesselbrock, M., Easton, C., Bucholz, K. K., Schuckit, M., & Hesselbrock, V. (1999). A validity study of the SSAGA-a comparison with the SCAN. Addiction, 94 (9), 1361–1370.

77

Glass, M., Faull, R. L. M., & Dragunow, M. (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 77 (2), 299–318.

78

Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153 (2), 199–215.

79

Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2005). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews, 27 (1), 73–100.

80

Breslau, N., Kilbey, M. M., & Andreski, P. (1991). Nicotine dependence, major depression, and anxiety in young adults. Archives of General Psychiatry, 48 (12), 1069–1074.

81

Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D., Van Gaal, L. F., & RIO-Diabetes Study Group. (2006). Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. The Lancet, 368 (9548), 1660–1672.

82

Marsicano, G., & Lutz, B. (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience, 11 (12), 4213–4225.

83

Mailleux, P., & Vanderhaeghen, J. J. (1992). Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience, 48 (3), 655–668.

84

Van Os, J., Bak, M., Hanssen, M., Bijl, R. V., De Graaf, R., & Verdoux, H. (2002). Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology, 156 (4), 319–327.

85

Kirkham, T. C., Williams, C. M., Fezza, F., & Marzo, V. D. (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 136 (4), 550–557.

86

Hanuš, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., ... & Mechoulam, R. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences, 98 (7), 3662–3665.

87

Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences, 92 (8), 3376–3380.

88

Gerard, C. M., Mollereau, C., Vassart, G., & Parmentier, M. (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal, 279 (1), 129–134.

89

Di Marzo, V. (2008). Targeting the endocannabinoid system: to enhance or reduce? Nature Reviews Drug Discovery, 7 (5), 438–455.

90

Degenhardt, L., & Hall, W. (2012). Extent of illicit drug use and dependence, and their contribution to the global burden of disease. The Lancet, 379 (9810), 55–70.

91

Grant, B. F., Saha, T. D., Ruan, W. J., Goldstein, R. B., Chou, S. P., Jung, J., ... & Hasin, D. S. (2016). Epidemiology of DSM-5 drug use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions–III. JAMA Psychiatry, 73 (1), 39–47.

92

Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 413 (6855), 527–531.

93

Hall, W., & Degenhardt, L. (2009). Adverse health effects of non-medical cannabis use. The Lancet, 374 (9698), 1383–1391.

94

Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T., & Ueda, N. (2004). Molecular characterization of a phospholipase D generating anandamide and its congeners. Journal of Biological Chemistry, 279 (7), 5298–5305.

95

Di, S., Malcher-Lopes, R., Halmos, K. C., & Tasker, J. G. (2003). Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. Journal of Neuroscience, 23 (12), 4850–4857.

96

Di Marzo, V., & Matias, I. (2005). Endocannabinoid control of food intake and energy balance. Nature Neuroscience, 8 (5), 585–589.

97

Linszen, D. H., Dingemans, P. M., & Lenior, M. E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry, 51 (4), 273–279.

98

Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006). Endocannabinoid-mediated synaptic plasticity in the CNS. Annual Review of Neuroscience, 29, 37–76.

99

Pertwee, R. G. (2001). Cannabinoid receptors and pain. Progress in Neurobiology, 63 (5), 569–611.

100

Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., ... & Duranti, A. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature, 435 (7045), 1108–1112.